Review
CMV and Immunosenescence: from basics to clinics
1 Immunology Unit, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Reina Sofia University Hospital-University of Cordoba, Cordoba, Spain
2 Immunology Unit, Department of Physiology, University of Extremadura, Caceres, Spain
3 University of Michigan, Department of Epidemiology, Center for Social Epidemiology and Population Health, Ann Arbor, Michigan, USA
4 Division of Infection and Immunity, University College London, London, UK
5 Infections and Immunity, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
6 School of Cancer Sciences, University of Birmingham, Birmingham, UK
7 University of Amsterdam, Amsterdam, The Netherlands
8 Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany
9 Department of Internal Medicine II, Center for Medical Research, University of Tübingen, Tübingen, Germany
10 Laboratory of Molecular Immune-Biology, Hospital General Universitario Gregorio Marañón, Madrid and Laboratory of Immunovirology; Infectious Diseases Service, IBiS, Seville, Spain
11 Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, USA
12 Research Center on Aging, Sherbrooke, Canada
13 Regenerative Medicine Group, Cranfield Health, Cranfield University, Cranfield, UK
14 Institute for Biomedical Aging Research, University of Innsbruck, Innsbruck, Austria
15 Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, USA
16 University of Tampere, Medical School, Tampere, Finland
17 Brighton and Sussex Medical School, Brighton, UK
18 Singapore Immunology Network, Singapore, Singapore
19 IMIM (Hospital del Mar Research Institute), Univ. Pompeu Fabra, Barcelona, Spain
20 Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
21 University of British Columbia, Vancouver, Canada
22 Department of Clinical Immunology, University Hospital Alexandrovska, Sofia, Bulgaria
23 Department of Immunobiology and the Arizona Center on Aging, University of Arizona College of Medicine, Tucson, Arizona, USA
24 University of Birmingham, Birmingham, UK
25 Department of Internal Medicine and Biomedical Sciences, University of Parma, Parma, Italy
26 Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands
27 Division of Geriatric Medicine and Gerontology, Biology of Healthy Aging Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
28 University of Cambridge Department of Medicine Addenbrookes Hospital, Cambridge, UK
29 Department of Clinical Immunology and Transplantology, Medical University of Gdansk, Gdansk, Poland
30 Mannheim Institute of Public Health, Social and Preventive Medicine (MIPH), University of Heidelberg, Mannheim Medical Faculty, Mannheim, Germany
Immunity & Ageing 2012, 9:23 doi:10.1186/1742-4933-9-23
Published: 31 October 2012Abstract
Alone among herpesviruses, persistent Cytomegalovirus (CMV) markedly alters the numbers and proportions of peripheral immune cells in infected-vs-uninfected people. Because the rate of CMV infection increases with age in most countries, it has been suggested that it drives or at least exacerbates “immunosenescence”. This contention remains controversial and was the primary subject of the Third International Workshop on CMV & Immunosenescence which was held in Cordoba, Spain, 15-16th March, 2012. Discussions focused on several main themes including the effects of CMV on adaptive immunity and immunosenescence, characterization of CMV-specific T cells, impact of CMV infection and ageing on innate immunity, and finally, most important, the clinical implications of immunosenescence and CMV infection. Here we summarize the major findings of this workshop.
